1 김태형, "메티실린 내성 포도구균(MRSA) 감염에 대한 Arbekacin의임상적 효과 및 안전성" 대한내과학회 65 (65): 239-244, 2003
2 Walsh TR, "prevalence and mechanisms ofvancomycin resistance in Staphylococcus aureus" 56 : 657-675, 2002
3 Sievert DM, "Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006" 46 : 668-674, 2008
4 Hwang JH, "Theusefulness of arbekacin compared to vancomycin" 31 : 1663-1666, 2012
5 이종한, "Staphylococcus 균종과 그람음성 간균에 대한 Arbekacin의 시험관내 항균력" 대한진단검사의학회 27 (27): 292-297, 2007
6 Lodise TP, "Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalizedpatients" 49 : 507-514, 2009
7 Manjunath G, "Prediction equationsto estimate glomerular filtration rate: an update" 10 : 785-792, 2001
8 Sato R, "Pharmacokinetic-pharmacodynamic relationship of arbekacinfor treatment of patients infected with methicillin-resistantStaphylococcus aureus" 50 : 3763-3769, 2006
9 Nichols RL, "Optimal treatment of complicated skin andskin structure infections" 44 (44): 19-23, 1999
10 정경태, "Nationwide Surveillance Study of Vancomycin-Intermediate Staphylococcus aureus Strains in Korean Hospitals from 2001 to 2006" 한국미생물·생명공학회 20 (20): 637-642, 2010
1 김태형, "메티실린 내성 포도구균(MRSA) 감염에 대한 Arbekacin의임상적 효과 및 안전성" 대한내과학회 65 (65): 239-244, 2003
2 Walsh TR, "prevalence and mechanisms ofvancomycin resistance in Staphylococcus aureus" 56 : 657-675, 2002
3 Sievert DM, "Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006" 46 : 668-674, 2008
4 Hwang JH, "Theusefulness of arbekacin compared to vancomycin" 31 : 1663-1666, 2012
5 이종한, "Staphylococcus 균종과 그람음성 간균에 대한 Arbekacin의 시험관내 항균력" 대한진단검사의학회 27 (27): 292-297, 2007
6 Lodise TP, "Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalizedpatients" 49 : 507-514, 2009
7 Manjunath G, "Prediction equationsto estimate glomerular filtration rate: an update" 10 : 785-792, 2001
8 Sato R, "Pharmacokinetic-pharmacodynamic relationship of arbekacinfor treatment of patients infected with methicillin-resistantStaphylococcus aureus" 50 : 3763-3769, 2006
9 Nichols RL, "Optimal treatment of complicated skin andskin structure infections" 44 (44): 19-23, 1999
10 정경태, "Nationwide Surveillance Study of Vancomycin-Intermediate Staphylococcus aureus Strains in Korean Hospitals from 2001 to 2006" 한국미생물·생명공학회 20 (20): 637-642, 2010
11 Hiramatsu K, "Methicillin-resistant Staphylococcus aureus clinicalstrain with reduced vancomycin susceptibility" 40 : 135-136, 1997
12 Wang G, "Increased vancomycinMICs for Staphylococcus aureus clinical isolatesfrom a university hospital during a 5-year period" 44 : 3883-3886, 2006
13 이경원, "Increase of Ceftazidime- and Fluoroquinolone-Resistant Klebsiella pneumoniae and Imipenem-Resistant Acinetobacter spp. in Korea: Analysis of KONSAR Study Data from 2005 and 2007" 연세대학교의과대학 51 (51): 901-911, 2010
14 Holmberg SD, "Health and economicimpacts of antimicrobial resistance" 9 : 1065-1078, 1987
15 Kirby JT, "Geographic variations in garenoxacin (BMS284756) activitytested against pathogens associated with skin and softtissue infections: report from the SENTRY AntimicrobialSurveillance Program (2000)" 43 : 303-309, 2000
16 Ryu JS, "Efficacy of teicoplaninin gram-positive bacterial infection" 24 : 183-189, 1992
17 Suzuki K, "Efficacy and safety of arbekacin for staphylococcal infection in the NICU" 45 : 301-306, 2003
18 Lee DG, "Efficacies of vancomycin, arbekacin, andgentamicin alone or in combination against methicillinresistantStaphylococcus aureus in an in vitro infectiveendocarditis model" 47 : 3768-3773, 2003
19 Moet GJ, "Contemporary causes of skin and soft tissue infections inNorth America, Latin America, and Europe: report from theSENTRY Antimicrobial Surveillance Program (1998-2004)" 57 : 7-13, 2007
20 Watanabe T, "Comparativestudies of the bactericidal, morphological and post-antibioticeffects of arbekacin and vancomycin against methicillinresistantStaphylococcus aureus" 39 : 471-476, 1997
21 Wilson SE, "Clinical trial results with linezolid, an oxazolidinone,in the treatment of soft tissue and postoperativegram-positive infections" 2 : 25-35, 2001
22 Nichols RL, "Clinical presentations of softtissueinfections and surgical site infections" 33 (33): 84-93, 2001
23 Liu C, "Clinical practice guidelines bythe infectious diseases society of america for the treatmentof methicillin-resistant Staphylococcus aureus infectionsin adults and children: executive summary" 52 : 285-292, 2011
24 Kobayashi Y, "Arbekacin" 5 : 227-230, 1995
25 Wie SH, "Antimicrobialactivities of arbekacin against clinical isolates of Staphylococcusaureus and coagulase-negative Staphylococcusspecies" 33 : 254-260, 2001
26 Hamilton-Miller JM, "Activity of the semi-synthetickanamycin B derivative, arbekacin against methicillinresistantStaphylococcus aureus" 35 : 865-868, 1995